A Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Pregabalin is a commonly used therapy currently recommended as first‐line treatment for a number of neuropathic pain (NeP) conditions. Since licensure, a number of clinical trials of pregabalin in different NeP conditions have been completed from which additional data on safety and tolerability can be drawn. In this analysis, patient‐level data from 31 randomized clinical trials of pregabalin in peripheral NeP sponsored by Pfizer were pooled and assessed for incidence of adverse events (AE s). Incidence by age, disease condition, and race, together with risk differences and time to onset and resolution of AE s, was assessed. In total, 7,510 patients were included: 4,884 on pregabalin (representing 805 patient‐years treatment) and 2,626 on placebo. Pregabalin vs. placebo risk analysis identified 9 AE s with a risk difference, for which the lower limit of the 95% confidence interval (CI) was > 1%: dizziness (risk difference [95% CI]: (17.0 [15.4 to 18.6]), somnolence (10.8 [9.5 to 12.1]), peripheral edema (5.4 [4.3 to 6.4]), weight increase (4.7 [3.9 to 5.5]), dry mouth (2.9 [2.1 to 3.8]), constipation (2.3 [1.5 to 3.2]), blurred vision (2.2 [1.6 to 2.9]), balance disorder (2.0 [1.5 to 2.5]), and euphoric mood (1.6 [1.2 to 2.0]). The most common AE s, dizziness and somnolence, typically emerged within the first 1 to 2 weeks of treatment and resolved 1 to 2 weeks later, without resulting in cessation of treatment. The data from this review provide information, indicating which AE s may be expected in patients treated with pregabalin, and suggest that careful dose titration to the highest tolerable dose is the most appropriate approach in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
Treatment of neuropathic pain: an overview of recent guidelines.
O'Connor, A. B., & Dworkin, R. H. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.04.007 · Cited by 781
Bril, V., England, J., Franklin, G. M., Backonja, M., Cohen, J., Del Toro, D., Feldman, E., Iverson, D. J., Perkins, B., Russell, J. W., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166ebe · Cited by 634
Tesfaye, S., Wilhelm, S., Lledo, A., Schacht, A., Tölle, T., Bouhassira, D., Cruccu, G., Skljarevski, V., & Freynhagen, R. (2013) · Pain · doi:10.1016/j.pain.2013.05.043 · Cited by 311
Self-citationBaron, R., Freynhagen, R., Tölle, T. R., Cloutier, C., Leon, T., Murphy, K. T., & Phillips, K. (2010) · Pain · doi:10.1016/j.pain.2010.04.013 · Cited by 163
Self-citation
Cited by
Onakpoya, I. J., Thomas, E. T., Lee, J. J., Goldacre, B., & Heneghan, C. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-023600 · Cited by 132
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
“The most common adverse events related to pregabalin are similar to those of gabapentin, including: dizziness, somnolence, euphoria, peripheral edema and weight gain [77, 87, 88].”
BackgroundArnold, L. M., McCarberg, B. H., Clair, A. G., Whalen, E., Thomas, N., Jorga, A., Pauer, L., Vissing, R., & Park, P. W. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1384691 · Cited by 27
“As expected from the known tolerability profile of pregabalin [1,2,35,36],”
BackgroundSelf-citationDoes duration of neuropathic pain impact the effectiveness of pregabalin?
Pérez, C., Latymer, M., Almas, M., Ortiz, M., Clair, A., Parsons, B., & Varvara, R. (2017) · Pain Practice · doi:10.1111/papr.12469 · Cited by 19
“A recent comprehensive analysis reported adverse events and their time to onset and resolution in a broader selection of clinical trials of pregabalin in patients with pain disorders (including most of the studies in this analysis).(43) Analysis of adverse events in Table 4.”
BackgroundSelf-citation
Metadata
- Authors
- Freynhagen, R., Serpell, M., Emir, B., Whalen, E., Parsons, B., Clair, A., & Latymer, M.
- Venue
- Pain Practice
- Publisher
- Wiley
- Published
- 2013-11-27
- Volume
- 15
- Issue
- 1
- Pages
- 47-57
- ISSN
- 1530-7085 (ISSN-L)
- 1533-2500
- OpenAlex
- W2063925605
- Cited by
- 82
- References
- 5
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain. https://app.cochat.ai/papers/10.1111/papr.12146
- The paper
- Freynhagen, R., Serpell, M., Emir, B., Whalen, E., Parsons, B., Clair, A., & Latymer, M. (2015). A Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain. Pain Practice. https://doi.org/10.1111/papr.12146
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.